Page last updated: 2024-11-02

pirenzepine and Prader-Willi Syndrome

pirenzepine has been researched along with Prader-Willi Syndrome in 1 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Prader-Willi Syndrome: An autosomal dominant disorder caused by deletion of the proximal long arm of the paternal chromosome 15 (15q11-q13) or by inheritance of both of the pair of chromosomes 15 from the mother (UNIPARENTAL DISOMY) which are imprinted (GENETIC IMPRINTING) and hence silenced. Clinical manifestations include MENTAL RETARDATION; MUSCULAR HYPOTONIA; HYPERPHAGIA; OBESITY; short stature; HYPOGONADISM; STRABISMUS; and HYPERSOMNOLENCE. (Menkes, Textbook of Child Neurology, 5th ed, p229)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Phan, TG1
Yu, RY1
Hersch, MI1

Other Studies

1 other study available for pirenzepine and Prader-Willi Syndrome

ArticleYear
Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome.
    The Medical journal of Australia, 1998, Aug-17, Volume: 169, Issue:4

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Hypothermia

1998